Bought-and-paid-for optionality: the company already holds a second, unmonetized position it can switch on at will
The model's full reasoning — Q1 2018 call → NOThe question asks whether management describes a second, largely unmonetized position that the company already possesses, whose future use is largely within the company's own control, and whether management is actively deciding how and when to turn that holding into revenue. Let me analyze the transcript for such a situation. Key elements to look for: 1. A real holding the company already has, not what pays the bills today 2. It's currently producing little or nothing, and management says so 3. Management is now working on converting it, and the decision is largely theirs Let me scan the transcript for potential candidates: - The NovaSeq rollout - this is being monetized already, it's the main business - The oncology collaborations with Loxo and BMS - these are partnerships, but they're just announced, not yet producing revenue. However, these are collaborations to develop companion diagnostics, not a "holding" the company already has that's dormant. - The iSeq platform - launched, beta testing, not yet scaled. But this is a new product being developed/rolled out, not a dormant holding. - The Helix investment - this is an investment, being monetized through the partnership. - The microarray business - this is producing revenue, it's the main business. Let me think about what could be a "second, largely unmonetized position." The question is quite specific: a holding that exists and is in hand now, currently producing little or nothing, and management is working on converting it with the decision largely theirs. Looking at the transcript, the oncology collaborations with Loxo and BMS are mentioned. These are partnerships to develop companion diagnostics. But these are just announced - they're not yet a "holding" that's dormant. They're new initiatives. What about the installed base of NovaSeq customers? The company has an installed base it could sell more to. But that's the ordinary course of business. What about the "TruSight Tumor 170 test" and "TruSight Oncology 500" - these are products being developed for companion diagnostics. But they're being developed, not already in hand and dormant. Let me reconsider. The question asks about a "second, largely unmonetized position" - something real the company holds today, beyond the business currently producing results.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| LEGH | Legacy Housing Corporation | Q4 2023 | 2024-03-18 | C |
| DM | Desktop Metal, Inc. | Q2 2022 | 2022-08-08 | F |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| CLMT | Calumet Specialty Products Partners, L.P | Q1 2018 | 2018-05-16 | C+ |
| UPLD | Upland Software, Inc. | Q4 2017 | 2018-03-08 | C+ |
| FCX | Freeport-McMoRan Inc. | Q3 2017 | 2017-10-25 | D |
CLMT · Q1 2018 → YESThe question is about whether management describes an already possessed second, largely unmonetized position that they can switch on themselves. YES The transcript shows management describing the Biosynthetic Technologies acquisition as a real holding already in hand (completed Q1 2018, with 71 issued patents, 76 pending, exclusive USDA license), separate from the operations generating current results. It contributes little today (only $4M acquisition expenses noted, no revenue yet), and management is actively deciding how and when to monetize it—via low-capex proof-of-concept at the Missouri esters plant, new product innovation center, and third-party involvement—within their control. This fits the criteria as a dormant capability they are now sequencing for revenue.
LEGH · Q4 2023 → YESThe question is about whether management describes a second, largely unmonetized position that the company already possesses, whose future use is largely within their control, and they're actively dec...YES The transcript shows management describing land holdings as a second, largely unmonetized position separate from current operations. They hired a dedicated team to prioritize and accelerate land development, with Del Val Bastrop County as the top priority, and note capital is accelerating for this project.
FCX · Q3 2017 → YESThe question is about whether management describes a second, largely unmonetized position that they already possess, whose future use is within their control, and they're actively deciding how and whe...YES The transcript shows management describing exactly this situation: the company already owns large undeveloped sulfide resources (Lone Star oxide/sulfide, El Abra sulfide, Kisanfu cobalt, additional Grasberg material) that are not part of current production and contribute little to today's results.